Literature DB >> 24395225

In vitro screening test using Leishmania promastigotes stably expressing mCherry protein.

Paola Vacchina1, Miguel A Morales.   

Abstract

Transgenic Leishmania major and Leishmania donovani axenic promastigotes constitutively expressing mCherry were used for in vitro antileishmanial drug screening. This method requires minimal sample manipulation and can be easily adapted to automatic drug tests, allowing primary high-throughput screenings without the need for expensive and sophisticated instruments.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24395225      PMCID： PMC3957829          DOI： 10.1128/AAC.02224-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro.

Authors:  S W Kamau; F Grimm; A B Hehl
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 2.  A guide to choosing fluorescent proteins.

Authors:  Nathan C Shaner; Paul A Steinbach; Roger Y Tsien
Journal:  Nat Methods       Date:  2005-12       Impact factor: 28.547

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes.

Authors:  Miriam Rolón; Celeste Vega; José A Escario; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2006-02-28       Impact factor: 2.289

5.  Comparison of a novel redox dye cell growth assay to the ATP bioluminescence assay.

Authors:  R C Squatrito; J P Connor; R E Buller
Journal:  Gynecol Oncol       Date:  1995-07       Impact factor: 5.482

6.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.

Authors:  J O'Brien; I Wilson; T Orton; F Pognan
Journal:  Eur J Biochem       Date:  2000-09

Review 7.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

8.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Authors:  Jyotsna Mishra; Rentala Madhubala; Sarman Singh
Journal:  Parasitol Res       Date:  2012-12-18       Impact factor: 2.289

Review 9.  In vitro assays for evaluation of drug activity against Leishmania spp.

Authors:  Luciana Fumarola; Rosa Spinelli; Olga Brandonisio
Journal:  Res Microbiol       Date:  2004-05       Impact factor: 3.992

Review 10.  Leishmaniasis: current situation and new perspectives.

Authors:  P Desjeux
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.268
View more
  9 in total

1.  Intravital Microscopy Imaging of the Liver following Leishmania Infection: An Assessment of Hepatic Hemodynamics.

Authors:  Sreekanth Dasari; Pascal Weber; Camélia Makhloufi; Erica Lopez; Claire-Lise Forestier
Journal:  J Vis Exp       Date:  2015-07-28       Impact factor: 1.355

2.  Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major.

Authors:  Douglas R Rice; Paola Vacchina; Brianna Norris-Mullins; Miguel A Morales; Bradley D Smith
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 3.  Imaging flow cytometry analysis of intracellular pathogens.

Authors:  Viraga Haridas; Shahin Ranjbar; Ivan A Vorobjev; Anne E Goldfeld; Natasha S Barteneva
Journal:  Methods       Date:  2016-09-15       Impact factor: 3.608

4.  Leishmania phosphatase PP5 is a regulator of HSP83 phosphorylation and essential for parasite pathogenicity.

Authors:  Brianna Norris-Mullins; Joseph S Krivda; Kathryn L Smith; Micah J Ferrell; Miguel A Morales
Journal:  Parasitol Res       Date:  2018-07-08       Impact factor: 2.289

5.  Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani.

Authors:  P Vacchina; B Norris-Mullins; M A Abengózar; C G Viamontes; J Sarro; M T Stephens; M E Pfrender; L Rivas; M A Morales
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

6.  A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.

Authors:  P Vacchina; B Norris-Mullins; E S Carlson; M A Morales
Journal:  Parasit Vectors       Date:  2016-12-01       Impact factor: 3.876

7.  Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic Leishmania: Valuable Tools for Future Molecular Analysis.

Authors:  Andrés Vacas; Conor Sugden; Óscar Velasco-Rodriguez; Miriam Algarabel-Olona; José Peña-Guerrero; Esther Larrea; Celia Fernández-Rubio; Paul A Nguewa
Journal:  J Parasitol Res       Date:  2017-02-13

8.  Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.

Authors:  Kimbra G Turner; Paola Vacchina; Maricela Robles-Murguia; Mariha Wadsworth; Mary Ann McDowell; Miguel A Morales
Journal:  PLoS Negl Trop Dis       Date:  2015-07-31

9.  Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.

Authors:  Sarah L Berry; Hamza Hameed; Anna Thomason; Marissa L Maciej-Hulme; Somaia Saif Abou-Akkada; Paul Horrocks; Helen P Price
Journal:  PLoS Negl Trop Dis       Date:  2018-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.